Bristol-Myers Squibb (BMY)

64.16 -2.71 (4.05%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (2/6/20)
- M&A (9/30/19 *Est)

Latest Headlines

Bristol-Myers Squibb (BMY) Hits Low, Down 3% January 24, 2020 10:31 AM - StreetInsider Kitov Pharma (KTOV) Receives Notice of Intention to Grant European Patent Covering the Use of NT-219 in Combination with EGFR Inhibitors January 24, 2020 8:11 AM - StreetInsider Kitov Pharma Receives Notice of Intention to Grant European Patent Covering the Use of NT-219 in Combination with EGFR Inhibitors January 24, 2020 8:11 AM - StreetInsider Kitov Pharma Receives Notice of Intention to Grant European Patent Covering the Use of NT-219 in Combination with EGFR Inhibitors January 24, 2020 8:10 AM - Globe NewsWire Form 5 BRISTOL MYERS SQUIBB CO For: Dec 31 Filed by: Caforio Giovanni January 17, 2020 5:41 PM - SEC Filing Form 5 BRISTOL MYERS SQUIBB CO For: Dec 31 Filed by: Bancroft Charles A January 17, 2020 5:41 PM - SEC Filing Form 4/A BRISTOL MYERS SQUIBB CO For: Dec 31 Filed by: VESSEY RUPERT January 15, 2020 5:05 PM - SEC Filing Form 3 BRISTOL MYERS SQUIBB CO For: Jan 06 Filed by: Metcalfe Kathryn January 15, 2020 5:04 PM - SEC Filing Bristol-Myers Squibb (BMY) Announces FDA Accepts for Priority Review its Application for Opdivo Plus Yervoy in First-Line Non-Small Cell Lung Cancer January 15, 2020 7:01 AM - StreetInsider U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) in First-Line Non-Small Cell Lung Cancer January 15, 2020 6:59 AM - BizWire Bristol-Myers Squibb (BMY) Climbs 2.1% January 13, 2020 10:01 AM - StreetInsider Nektar Therapeutics (NKTR), Bristol-Myers Squibb (BMY) Amend Strategic Collaboration Agreement for bempegaldesleukin Plus Opdivo January 10, 2020 7:00 AM - StreetInsider Nektar Therapeutics and Bristol-Myers Squibb Amend Strategic Collaboration Agreement for bempegaldesleukin Plus Opdivo (nivolumab) January 10, 2020 6:59 AM - BizWire Bristol-Myers Squibb (BMY) call put ratio 5.7 calls to 1 put with focus on January 65 and 66 calls January 9, 2020 1:39 PM - StreetInsider Bristol-Myers Squibb (BMY) CMO says confident on track to receive U.S. approvals for drugs tied to Celgene CVR - Reuters Interview January 9, 2020 1:22 PM - StreetInsider Bristol-Myers Squibb (BMY) Trades at High, Up 2.5% January 9, 2020 10:44 AM - StreetInsider Kitov Pharma Announces Appointment of Bertrand Liang, M.D., Ph.D., as Chief Medical Officer January 9, 2020 8:36 AM - StreetInsider Kitov Pharma (KTOV) Announces Appointment of Bertrand Liang, M.D., Ph.D., as Chief Medical Officer January 9, 2020 8:35 AM - StreetInsider Kitov Pharma Announces Appointment of Bertrand Liang, M.D., Ph.D., as Chief Medical Officer January 9, 2020 8:34 AM - Globe NewsWire Bristol-Myers Squibb (BMY), Acceleron (XLRN) Announce NEJM Publishes Results of Pivotal Phase 3 Reblozyl MEDALIST Trial January 9, 2020 7:00 AM - StreetInsider New England Journal of Medicine Publishes Results of Pivotal Phase 3 Reblozyl® (luspatercept-aamt) MEDALIST Trial January 9, 2020 6:59 AM - BizWire Bristol-Myers Squibb Co. (BMY) PT Raised to $63 at UBS January 9, 2020 6:19 AM - StreetInsider Kitov Pharma Announces Closing of FameWave Acquisition January 8, 2020 7:31 AM - StreetInsider Kitov Pharma Announces Closing of FameWave Acquisition January 8, 2020 7:30 AM - Globe NewsWire Kitov Pharma Granted Additional 180-day Extension by Nasdaq to Comply with Bid Price Rule January 8, 2020 7:01 AM - StreetInsider Kitov Pharma Granted Additional 180-day Extension by Nasdaq to Comply with Bid Price Rule January 8, 2020 7:00 AM - Globe NewsWire Democratic lawmaker presses antitrust enforcers on company ties, settlements January 7, 2020 7:36 PM - StreetInsider Bristol-Myers Squibb Completes Divestment of Manufacturing Facility in Anagni, Italy   January 7, 2020 3:00 AM - BizWire Evotec And Bristol-Myers Squibb Expand iPSC Collaboration January 7, 2020 1:41 AM - StreetInsider Bristol-Myers Squibb to Present at the 38th Annual J.P. Morgan Healthcare Conference January 6, 2020 4:16 PM - BizWire Citi Resumes Bristol-Myers Squibb Co. (BMY) at Buy January 6, 2020 8:50 AM - StreetInsider Form 4/A BRISTOL MYERS SQUIBB CO For: Nov 20 Filed by: VESSEY RUPERT January 3, 2020 8:38 PM - SEC Filing Form 4/A BRISTOL MYERS SQUIBB CO For: Nov 20 Filed by: Elkins David V January 3, 2020 8:38 PM - SEC Filing Form 4/A BRISTOL MYERS SQUIBB CO For: Nov 20 Filed by: AHMED NADIM January 3, 2020 8:38 PM - SEC Filing Form 4 BRISTOL MYERS SQUIBB CO For: Dec 31 Filed by: VESSEY RUPERT January 3, 2020 7:01 PM - SEC Filing Form 4 BRISTOL MYERS SQUIBB CO For: Dec 31 Filed by: Elkins David V January 3, 2020 7:01 PM - SEC Filing Form 4 BRISTOL MYERS SQUIBB CO For: Dec 31 Filed by: YALE PHYLLIS R January 3, 2020 6:52 PM - SEC Filing Form 4 BRISTOL MYERS SQUIBB CO For: Dec 31 Filed by: Vousden Karen H January 3, 2020 6:52 PM - SEC Filing Form 4 BRISTOL MYERS SQUIBB CO For: Dec 31 Filed by: Storch Gerald L January 3, 2020 6:51 PM - SEC Filing Form 4 BRISTOL MYERS SQUIBB CO For: Dec 31 Filed by: Samuels Theodore R. II January 3, 2020 6:51 PM - SEC Filing Form 4 BRISTOL MYERS SQUIBB CO For: Dec 31 Filed by: Paliwal Dinesh C January 3, 2020 6:50 PM - SEC Filing Form 4 BRISTOL MYERS SQUIBB CO For: Dec 31 Filed by: LACY ALAN J January 3, 2020 6:50 PM - SEC Filing Form 4 BRISTOL MYERS SQUIBB CO For: Dec 31 Filed by: Haller Julia A January 3, 2020 6:50 PM - SEC Filing Form 4 BRISTOL MYERS SQUIBB CO For: Dec 31 Filed by: GROBSTEIN MICHAEL January 3, 2020 6:50 PM - SEC Filing Form 4 BRISTOL MYERS SQUIBB CO For: Dec 31 Filed by: Emmens Matthew January 3, 2020 6:49 PM - SEC Filing Form 4 BRISTOL MYERS SQUIBB CO For: Dec 31 Filed by: BONNEY MICHAEL W January 3, 2020 6:49 PM - SEC Filing Form 4 BRISTOL MYERS SQUIBB CO For: Dec 31 Filed by: BERTOLINI ROBERT J January 3, 2020 6:48 PM - SEC Filing Form 4 BRISTOL MYERS SQUIBB CO For: Dec 31 Filed by: Arduini Peter J January 3, 2020 6:48 PM - SEC Filing Bristol-Myers Squibb to Take Part at the Goldman Sachs 12th Annual Healthcare CEOs Unscripted Conference January 2, 2020 6:59 AM - BizWire Active options: BMY NIO AAPL TSLA WDC CSCO AMD CGC AMZN January 2, 2020 4:26 AM - StreetInsider Increasing unusual call option volume: BMY SYY FCEL MMP CARG WDC January 2, 2020 4:21 AM - StreetInsider More drugmakers hike U.S. prices as new year begins January 1, 2020 11:20 AM - StreetInsider Dealmakers eye cross-border M&A recovery as mega mergers roll on December 31, 2019 9:11 AM - StreetInsider William Blair Sees Biotech M&A Continuing in 2020; Issues Top 10 Predictions December 31, 2019 7:03 AM - StreetInsider Bristol-Myers Squibb (BMY) Receives EC Approval for Revlimid in Combination with Rituximab for the Treatment of Adult Patients with Previously Treated Follicular Lymphoma December 20, 2019 7:00 AM - StreetInsider Bristol-Myers Squibb Receives European Commission Approval for Revlimid® (lenalidomide) in Combination with Rituximab for the Treatment of Adult Patients with Previously Treated Follicular Lymphoma December 20, 2019 6:59 AM - BizWire Bristol-Myers Squibb (BMY), WindMIL Therapeutics to Collaborate on Clinical Research to Evaluate Marrow-Infiltrating Lymphocytes (MILs) in Combination with nivolumab (Opdivo) December 19, 2019 7:14 AM - StreetInsider WindMIL Therapeutics Announces Clinical Research Collaboration with Bristol-Myers Squibb to Evaluate Marrow-Infiltrating Lymphocytes (MILs™) in Combination with nivolumab (Opdivo®) for Treatment of December 19, 2019 7:01 AM - StreetInsider WindMIL Therapeutics Announces Clinical Research Collaboration with Bristol-Myers Squibb to Evaluate Marrow-Infiltrating Lymphocytes (MILs™) in Combination with nivolumab (Opdivo®) for Treatment of December 19, 2019 7:00 AM - Globe NewsWire Bristol-Myers Squibb to Announce Results for Fourth Quarter 2019 on February 6, 2020 December 19, 2019 6:59 AM - BizWire Bristol-Myers Squibb (BMY) Reports Submission of Biologics License Application to FDA for CAR T-Cell Therapy Lisocabtagene Maraleucel (liso-cel) December 18, 2019 4:19 PM - StreetInsider Bristol-Myers Squibb Announces Submission of Biologics License Application for CAR T-Cell Therapy Lisocabtagene Maraleucel (liso-cel) to FDA December 18, 2019 4:16 PM - BizWire Bristol-Myers Squibb Co. (BMY) PT Raised to $68 at Morgan Stanley December 18, 2019 8:28 AM - StreetInsider Bristol-Myers Squibb Co. (BMY) PT Raised to $68 at Morgan Stanley December 18, 2019 6:15 AM - StreetInsider Roche to complete $4.3 billion Spark deal as regulators give all clear December 16, 2019 5:40 PM - StreetInsider Bristol-Myers Squibb (BMY) Wins Patent Royalty Fight Against Gilead Sciences (GILD), Awarded $585M in Damages, Plus Royalty - Bloomberg December 13, 2019 2:29 PM - StreetInsider UPDATE: Argus Upgrades Bristol-Myers Squibb Co. (BMY) to Buy December 13, 2019 7:15 AM - StreetInsider Bristol-Myers Squibb Announces Leadership Changes December 13, 2019 7:00 AM - BizWire Bristol-Myers business development head Biondi departs December 12, 2019 1:12 PM - StreetInsider Form 8-K/A BRISTOL MYERS SQUIBB CO For: Sep 11 December 11, 2019 4:53 PM - SEC Filing Bristol-Myers Squibb (BMY) Presents OS and Safety Data From Pivotal CC-486 Study QUAZAR AML-001 December 10, 2019 7:31 AM - StreetInsider Bristol-Myers Squibb Presents Overall Survival and Safety Data From Pivotal CC-486 Study QUAZAR AML-001 December 10, 2019 7:30 AM - BizWire bluebird bio (BLUE), Bristol-Meyers Squibb (BMY) Highlight Updated Data from Ongoing Ph. 1 Study of BCMA-Targeted CAR T Cell Therapy bb21217 in Relapsed/Refractory Multiple Myeloma December 10, 2019 5:58 AM - StreetInsider Choppy markets leave U.S. bank bonus decisions in limbo December 10, 2019 12:05 AM - StreetInsider bluebird bio and Bristol-Myers Squibb Present Updated Data from Ongoing Phase 1 Study of BCMA-Targeted CAR T Cell Therapy bb21217 in Relapsed/Refractory Multiple Myeloma at 61st ASH Annual Meeting and December 9, 2019 6:15 PM - BizWire Bristol-Myers Squibb (BMY), Acceleron (XLRN) Announce Reblozyl Studies Evaluating Treatment of Anemia in Rare Blood Diseases Presented at ASH December 9, 2019 4:47 PM - StreetInsider Form 4 BRISTOL MYERS SQUIBB CO For: Dec 05 Filed by: Dubow Adam December 9, 2019 4:44 PM - SEC Filing Reblozyl® (luspatercept-aamt) Studies Evaluating Treatment of Anemia in Rare Blood Diseases Presented at American Society of Hematology (ASH) Annual Meeting December 9, 2019 4:30 PM - BizWire Bristol-Myers Squibb (BMY) Trades at Session High, Up 2.25% December 9, 2019 11:44 AM - StreetInsider Bristol-Myers Squibb (BMY) option implied volatility low December 9, 2019 10:37 AM - StreetInsider Options expected to have increasing volume: PCG M BMY CGC December 9, 2019 9:46 AM - StreetInsider Popular stocks with increasing unusual: OXY FCX DHR UBER BMY December 9, 2019 4:55 AM - StreetInsider Bristol-Myers Squibb Announces Studies Evaluating liso-cel in Multiple Additional Patient Populations, Site of Care and Disease Areas Presented at American Society of Hematology (ASH) Annual Meeting December 8, 2019 4:30 PM - BizWire Findings Released from Real-World Data Analysis of Eliquis (apixaban) for the Treatment of Venous Thromboembolism in Patients with Active Cancer December 7, 2019 4:00 PM - BizWire Bristol-Myers Squibb Announces Liso-Cel Met Primary and Secondary Endpoints in TRANSCEND NHL 001 Study December 7, 2019 2:00 PM - BizWire Bristol-Myers Squibb (BMY), bluebird bio (BLUE) Announce Positive Top-line Results from Pivotal Phase 2 KarMMa Study of Ide-cel in R/R Multiple Myeloma December 6, 2019 4:17 PM - StreetInsider Bristol-Myers Squibb and bluebird bio Announce Positive Top-line Results from the Pivotal Phase 2 KarMMa Study of Ide-cel in Relapsed and Refractory Multiple Myeloma December 6, 2019 4:16 PM - BizWire Bristol-Myers Squibb (BMY), Acceleron Pharma (XLRN) Announces FDA Will Not Review Reblozyl at ODAC Meeting December 6, 2019 12:07 PM - StreetInsider Bristol-Myers Squibb and Acceleron Pharma Provide Update on FDA Advisory Committee for Reblozyl® (luspatercept-aamt) December 6, 2019 12:05 PM - BizWire Bristol-Myers Squibb (BMY) Raises Quarterly Dividend 9.8% to $0.45; 3% Yield December 5, 2019 4:24 PM - StreetInsider Bristol-Myers Squibb Announces Dividend Increase December 5, 2019 4:16 PM - BizWire Form 4 BRISTOL MYERS SQUIBB CO For: Dec 02 Filed by: VESSEY RUPERT December 4, 2019 5:00 PM - SEC Filing Form 4 BRISTOL MYERS SQUIBB CO For: Dec 02 Filed by: Elkins David V December 4, 2019 4:59 PM - SEC Filing Form 4 BRISTOL MYERS SQUIBB CO For: Dec 02 Filed by: BOERNER CHRISTOPHER S. December 4, 2019 4:59 PM - SEC Filing Form 4 BRISTOL MYERS SQUIBB CO For: Dec 02 Filed by: AHMED NADIM December 4, 2019 4:58 PM - SEC Filing Bristol-Myers Squibb (BMY) Announces FDA Breakthrough Therapy Designation for ORENCIA to Help Prevent Acute Graft-Versus-Host Disease December 4, 2019 7:02 AM - StreetInsider Bristol-Myers Squibb Announces U.S. FDA Breakthrough Therapy Designation for ORENCIA® (abatacept) to Help Prevent Acute Graft-Versus-Host Disease, a Potentially Life-Threatening Complication After St December 4, 2019 6:59 AM - BizWire Form 4 BRISTOL MYERS SQUIBB CO For: Dec 01 Filed by: Eid Joseph December 3, 2019 5:29 PM - SEC Filing Bristol-Myers Squibb (BMY), Acceleron Pharma (XLRN) Announce FDA Advisory Committee Will Review Reblozyl for Use in Patients With Myelodysplastic Syndromes December 3, 2019 7:39 AM - StreetInsider Bristol-Myers Squibb and Acceleron Pharma Announce FDA Advisory Committee Will Review Reblozyl® (luspatercept-aamt) for Use in Patients With Myelodysplastic Syndromes December 3, 2019 7:38 AM - BizWire IFM Therapeutics Announces $55.5 Million Financing to Launch and Fund New Subsidiaries and Appointment of Dr. H. Martin Seidel as Chief Executive Officer December 2, 2019 6:30 AM - PR NewsWire Drugmakers slash prices in China to get on reimbursement list November 28, 2019 2:10 AM - StreetInsider Form 3 BRISTOL MYERS SQUIBB CO For: Nov 20 Filed by: Elkins David V November 27, 2019 5:59 PM - SEC Filing Form 4 BRISTOL MYERS SQUIBB CO For: Nov 20 Filed by: Elkins David V November 27, 2019 5:58 PM - SEC Filing Form 3 BRISTOL MYERS SQUIBB CO For: Nov 20 Filed by: VESSEY RUPERT November 27, 2019 5:49 PM - SEC Filing Form 4 BRISTOL MYERS SQUIBB CO For: Nov 20 Filed by: VESSEY RUPERT November 27, 2019 5:47 PM - SEC Filing Form 4 BRISTOL MYERS SQUIBB CO For: Nov 20 Filed by: AHMED NADIM November 27, 2019 5:47 PM - SEC Filing Form 4/A BRISTOL MYERS SQUIBB CO For: Nov 20 Filed by: Haller Julia A November 27, 2019 5:47 PM - SEC Filing Form 3 BRISTOL MYERS SQUIBB CO For: Nov 20 Filed by: Haller Julia A November 27, 2019 5:44 PM - SEC Filing Form 4/A BRISTOL MYERS SQUIBB CO For: Nov 20 Filed by: BONNEY MICHAEL W November 27, 2019 5:42 PM - SEC Filing Form 3 BRISTOL MYERS SQUIBB CO For: Nov 20 Filed by: BONNEY MICHAEL W November 27, 2019 5:39 PM - SEC Filing Form 4 BRISTOL MYERS SQUIBB CO For: Nov 20 Filed by: AHMED NADIM November 27, 2019 5:37 PM - SEC Filing Form 3 BRISTOL MYERS SQUIBB CO For: Nov 20 Filed by: AHMED NADIM November 27, 2019 5:37 PM - SEC Filing Form CERT BRISTOL MYERS SQUIBB CO November 27, 2019 8:50 AM - SEC Filing Form 8-A12B BRISTOL MYERS SQUIBB CO November 27, 2019 8:01 AM - SEC Filing Form 3 BRISTOL MYERS SQUIBB CO For: Nov 20 Filed by: YALE PHYLLIS R November 26, 2019 5:00 PM - SEC Filing Bristol-Myers Squibb to Hold Investor Webcast to Discuss ASH Highlights November 26, 2019 6:59 AM - BizWire Form S-8 BRISTOL MYERS SQUIBB CO November 25, 2019 5:19 PM - SEC Filing Form 8-K BRISTOL MYERS SQUIBB CO For: Nov 21 November 22, 2019 5:17 PM - SEC Filing Form 4 BRISTOL MYERS SQUIBB CO For: Nov 20 Filed by: Haller Julia A November 22, 2019 5:00 PM - SEC Filing Form 4 BRISTOL MYERS SQUIBB CO For: Nov 20 Filed by: BONNEY MICHAEL W November 22, 2019 5:00 PM - SEC Filing Form 4 BRISTOL MYERS SQUIBB CO For: Nov 20 Filed by: YALE PHYLLIS R November 22, 2019 4:58 PM - SEC Filing UPDATE: Morgan Stanley Starts Bristol-Myers Squibb Co. (BMY) at Equalweight November 22, 2019 7:35 AM - StreetInsider Bristol-Myers Squibb Company Announces Final Results of Exchange Offers for Celgene Corporation Notes November 21, 2019 6:59 AM - BizWire Amgen (AMGN) Completes Acquisition Of Otezla, Updates Guidance November 21, 2019 6:26 AM - StreetInsider Amgen Completes Acquisition Of Otezla® (apremilast) November 21, 2019 6:21 AM - PR NewsWire Form 8-K BRISTOL MYERS SQUIBB CO For: Nov 20 November 20, 2019 5:21 PM - SEC Filing Celgene Announces Plans to Transfer Listing of Celgene’s Contingent Value Rights Following Closing of Acquisition by Bristol-Myers Squibb November 20, 2019 4:18 PM - BizWire Bristol-Myers Squibb (BMY) Completes Acquisition of Celgene (CELG) November 20, 2019 4:16 PM - StreetInsider Bristol-Myers Squibb Completes Acquisition of Celgene, Creating a Leading Biopharma Company November 20, 2019 4:16 PM - BizWire New Research Demonstrates Second Direct Link Between Inflammasome Activation and Alzheimer's Disease November 20, 2019 1:41 PM - PR NewsWire Bristol-Myers Squibb (BMY) Extends Recent Decline, Down Another 1.5%, Down 5% in Three Days November 20, 2019 10:01 AM - StreetInsider Bristol-Myers Squibb (BMY) Announces Update on CheckMate -915 for Opdivo Plus Yervoy (ipilimumab) Versus Opdivo Alone in Patients with Resected High-Risk Melanoma and PD-L1 <1% November 20, 2019 6:59 AM - StreetInsider Bristol-Myers Squibb Announces Update on CheckMate -915 for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Versus Opdivo Alone in Patients with Resected High-Risk Melanoma and PD-L1 <1% November 20, 2019 6:58 AM - BizWire Thermo Fisher Scientific Set to Join S&P 100; ServiceNow to Join S&P 500 November 19, 2019 11:16 AM - PR NewsWire Pre-Open 11/19: (MYOV) (MDCO) (VKTX) Higher (I) (KSS) (HD) Lower (more...) November 19, 2019 9:13 AM - StreetInsider After-Hours Movers 11/18: (NOW) (OKTA) (CNK) Higher; (DJT) (WWD) (ASH) Lower (more...) November 18, 2019 5:52 PM - StreetInsider ServiceNow (NOW) to Replace Celgene (CELG) in the S&P 500; Thermo Fisher Scientific (TMO) Set to Join S&P 100 November 18, 2019 5:16 PM - StreetInsider Form CERT BRISTOL MYERS SQUIBB CO November 18, 2019 10:55 AM - SEC Filing ServiceNow (NOW) Gains on Chatter and as New CEO is Off and Running November 18, 2019 10:39 AM - StreetInsider ServiceNow (NOW) Ticks Higher on Chatter November 18, 2019 9:50 AM - StreetInsider Form 8-A12B BRISTOL MYERS SQUIBB CO November 18, 2019 8:31 AM - SEC Filing Bristol-Myers Squibb Co. (BMY) PT Raised to $62 at Cowen November 18, 2019 7:59 AM - StreetInsider Bristol-Myers Squibb Company Announces It Expects No Further Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes November 15, 2019 6:39 PM - BizWire Bristol-Myers (BMY) Receives FTC Clearance for Celgene (CELG) Acquisition, Deal Expected to Close Next Week November 15, 2019 5:57 PM - StreetInsider Form 8-K BRISTOL MYERS SQUIBB CO For: Nov 15 November 15, 2019 5:21 PM - SEC Filing Bristol-Myers Squibb Receives Clearance from U.S. Federal Trade Commission for Celgene Acquisition November 15, 2019 4:55 PM - BizWire Form 8-K BRISTOL MYERS SQUIBB CO For: Nov 15 November 15, 2019 8:01 AM - SEC Filing Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes November 15, 2019 6:59 AM - BizWire Form 8-K BRISTOL MYERS SQUIBB CO For: Nov 12 November 12, 2019 8:02 AM - SEC Filing Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes November 12, 2019 6:59 AM - BizWire Bristol-Myers Squibb (BMY) Announces FAA Accepts for Priority Review Application for Opdivo Plus Yervoy Combination for Patients with Previously Treated Advanced HCC November 11, 2019 7:00 AM - StreetInsider U.S. Food and Drug Administration Accepts for Priority Review Bristol-Myers Squibb’s Application for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Combination for Patients with Previously Treated Adva November 11, 2019 6:59 AM - BizWire FDA Approves Celgene's (CELG) Reblozyl for Rare Blood Disorder November 8, 2019 12:30 PM - StreetInsider Form 8-K BRISTOL MYERS SQUIBB CO For: Nov 07 November 7, 2019 8:01 AM - SEC Filing Bristol-Myers Squibb Underscores Precision-Focused Immunology Leadership with New Data on ORENCIA® (abatacept) in Early RA, ACPA-Positive Patients Presented at 2019 ACR/ARP Annual Meeting¹ November 7, 2019 6:59 AM - BizWire Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes November 7, 2019 6:58 AM - BizWire Form 4 BRISTOL MYERS SQUIBB CO For: Nov 05 Filed by: Schmukler Louis S November 6, 2019 4:55 PM - SEC Filing Form 4 BRISTOL MYERS SQUIBB CO For: Nov 05 Filed by: Elicker John E November 6, 2019 4:55 PM - SEC Filing Form 8-K BRISTOL MYERS SQUIBB CO For: Nov 05 November 5, 2019 8:01 AM - SEC Filing Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes November 5, 2019 6:59 AM - BizWire Bristol-Myers Squibb Co. (BMY) PT Raised to $67 at Goldman Sachs November 4, 2019 6:20 AM - StreetInsider Bristol-Myers Squibb Co. (BMY) PT Raised to $66 at Wolfe Research November 1, 2019 8:10 AM - StreetInsider Form 8-K BRISTOL MYERS SQUIBB CO For: Nov 01 November 1, 2019 8:01 AM - SEC Filing Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes November 1, 2019 6:59 AM - BizWire Form 10-Q BRISTOL MYERS SQUIBB CO For: Sep 30 October 31, 2019 9:41 AM - SEC Filing Form 8-K BRISTOL MYERS SQUIBB CO For: Oct 31 October 31, 2019 8:02 AM - SEC Filing Bristol-Myers posts better-than-expected results, Opdivo growth slows October 31, 2019 7:08 AM - StreetInsider Bristol-Myers Squibb (BMY) Tops Q3 EPS by 10c, Updattes FY Guidance October 31, 2019 7:02 AM - StreetInsider Bristol-Myers Squibb Reports Third Quarter Financial Results October 31, 2019 6:59 AM - BizWire Bristol-Myers Squibb to Take Part at the Wolfe Research Healthcare Conference October 30, 2019 4:15 PM - BizWire Form 8-K BRISTOL MYERS SQUIBB CO For: Oct 30 October 30, 2019 8:01 AM - SEC Filing Bristol-Myers Squibb Awards “Golden Tickets” for LabCentral to Carmine Therapeutics, STIMIT October 30, 2019 6:59 AM - BizWire Bristol-Myers Squibb Company Announces Extension of the Expiration Date for Exchange Offers for Celgene Corporation Notes October 30, 2019 6:59 AM - BizWire Merck sees ongoing Keytruda strength as its sales top $3 billion in quarter October 29, 2019 6:57 AM - StreetInsider Full Article List